The field of addiction treatment has seen the rise and fall of many drugs, and a new crisis is around the corner. Benzodiazepines (Xanax, Klonopin, etc) are surging to the forefront in unsettling ways: contributing to fatal overdoses, leading to extremely challenging recovery, and potentially fatal withdrawals. The rise of Gabapentinoid use among those with substance use disorders has lead to challenges in toxicology testing, new options in the transfer of addictions, and unrecognized potential for overdose and withdrawal. Join LICADD’s Medical Director Dr. Thomas Jan and Clinical Director Adam Birkenstock for an educational seminar on the future of addiction treatment to learn about these challenges and strategies for motivation and change in clients presenting with Benzodiazepine and Gabapentinoid use.
When registering, please be sure to include
If this information does not apply to you, please
CEU Certificates will be provided at the conclusion of the workshop as long as you were pre-registered
As per the NYSED, participants must be present for the entire workshop in order to
*ALPHA does not provide refunds for missed trainings. Please contact Amanda Cioffi